Onxeo completes €40.7 million rights issue
Clients Onxeo SA
Jones Day represented Onxeo SA, an innovative biopharmaceutical company specializing in the development of orphan oncology drugs, in connection with its €40.7 million (US$50.6 million) issuance of Ordinary Shares. Natixis and Oddo & Cie acted as joint lead managers and joint bookrunners. This was the first simultaneous public offering in France and Denmark.